Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-04-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
独立董事对担保等事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion report related to the company's 7th board of directors' 23rd meeting. It covers multiple topics including external guarantees, related party transactions, profit distribution plan for 2021, internal control evaluation report for 2021, reappointment of the audit firm for 2022, use of idle raised funds for cash management, entrusted financial management, foreign exchange derivatives business, guarantees by controlling shareholders, repurchase and cancellation of restricted stock incentive plan shares, and board re-election proposals. The document references the 2021 fiscal year and includes detailed opinions on financial and governance matters. It is not a full annual report but rather a formal independent opinion on various board meeting agenda items, including audit and financial matters. This type of document is typically classified as an Audit Report / Information (AR) because it contains audit-related opinions and internal control evaluations, but is not the full annual report (10-K). The length (5169 characters) and content support this classification rather than a brief announcement or a full report. FY 2021
2022-04-12 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021年度独立董事述职报告" which translates to "2021 Annual Independent Director's Work Report". It details the independent director's activities, opinions on various board meetings, supervisory roles, and compliance with laws and regulations during the year 2021. The content includes detailed independent opinions on company matters such as stock incentive plans, use of raised funds, audit firm reappointment, internal control evaluation, and other governance-related issues. It is a comprehensive report on the independent director's duties and oversight for the year, rather than a general annual report or financial statement. This type of document is typically classified under Board/Management Information (MANG) as it relates to management and board activities and disclosures about governance and oversight by directors. The document is lengthy (over 13,000 characters) and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. It is not a call transcript, earnings release, or other categories. Therefore, the best fit is MANG with high confidence.
2022-04-12 Chinese
关于控股子公司在研产品F-627项目的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the progress of a clinical product (F-627) and the delay in FDA approval due to travel restrictions preventing an on-site inspection. It does not contain financial statements, audit results, or detailed financial data. The document is relatively short (1255 characters) and serves as an update on regulatory and operational progress related to a product approval process. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a certification or voting result. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about the status of a product approval process and related risks, without detailed financial data or report attachments.
2022-03-31 Chinese
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the progress of providing guarantees for its wholly-owned subsidiary. It details the guarantee contract, the financial status of the subsidiary, and the board's approval of the guarantee within previously approved limits. The document is relatively short (3565 characters) and focuses on a specific financing guarantee update rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about a financing-related guarantee. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-23 Chinese
关于全资子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (672 characters) regarding the re-certification of a wholly-owned subsidiary as a high-tech enterprise, including details about the certificate and its impact on tax rates. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an official company announcement about a regulatory or tax status update, not a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-09 Chinese
关于控股股东部分股份质押展期的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the extension of a pledge on shares held by a controlling shareholder. It details the number of shares pledged, the pledge period, and risk warnings related to the pledge. There are no financial statements, earnings data, or management discussions. The document is short (1884 characters) and serves as a disclosure of a shareholder's share pledge extension, which is a capital structure related update. This fits the category of Capital/Financing Update (CAP).
2022-02-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.